Bryan, Garnier & Co Reiterates Buy Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reiterated by research analysts at Bryan, Garnier & Co in a note issued to investors on Monday.
Several other research analysts have also weighed in on the company. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. Deutsche Bank AG reiterated a “hold” rating and set a GBX 1,700 ($20.72) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 28th. Jefferies Group upgraded GlaxoSmithKline plc to a “buy” rating and lifted their target price for the stock from GBX 1,650 ($20.11) to GBX 2,000 ($24.38) in a report on Thursday, July 14th. BNP Paribas reiterated a “neutral” rating and set a GBX 1,430 ($17.43) target price on shares of GlaxoSmithKline plc in a report on Sunday, July 3rd. Finally, Independent Research GmbH set a GBX 1,800 ($21.94) target price on GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Thursday, August 4th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of GBX 1,687.13 ($20.56).
Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.54% on Monday, hitting GBX 1665.00. The stock had a trading volume of 10,578,517 shares. The firm’s 50 day moving average is GBX 1,651.06 and its 200-day moving average is GBX 1,566.16. GlaxoSmithKline plc has a one year low of GBX 1,277.25 and a one year high of GBX 1,745.56. The stock’s market capitalization is GBX 80.94 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/bryan-garnier-co-reiterates-buy-rating-for-glaxosmithkline-plc-gsk-2.html
The firm also recently announced a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 19 ($0.23) per share. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.
In other GlaxoSmithKline plc news, insider Witty,Sir Andrew P sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60). Also, insider Slaoui,Moncef bought 28 shares of the business’s stock in a transaction on Friday, August 12th. The shares were acquired at an average price of GBX 2,208 ($26.91) per share, with a total value of £618.24 ($753.49).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.